Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
- Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled corticosteroid (ICS) monotherapy[1]
- QUARTZ is the first completed study of the phase III PLATINUM clinical development program which evaluates both QMF149 (indacaterol and mometasone furoate) and QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate)
- Novartis is aiming to reimagine inhaled asthma care by developing once daily fixed dose combination treatments, delivered with the dose-confirming Breezhaler??device, to help asthma patients achieve better control
Peter Zuest Novartis Global External Communications +41 79 899 9812 (mobile) peter.zuest@novartis.com?? Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Beyza Oezel Global Head, Respiratory Communications +41 61 696 9503 (direct) +41 79 720 4038 (mobile) beyza.oezel@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 862 778 3275 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 862 778 3258 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |